Fauquert JL, et al. - Researchers tested the safety as well as the efficacy of the oral build-up phase of GIDOIT (gastrointestinal delivery oral immunotherapy) using sealed capsules of peanut to bypass the upper gastrointestinal tract (a new approach) in an exclusively adolescent population with a history of a clinical allergic reaction after peanut ingestion. They found that clinical and immunological efficacy of the GIDOIT protocol was evident. Furthermore, this protocol showed an acceptable level of safety. Weak oropharyngeal symptoms, no dysphagia, mild digestive events and few severe systemic adverse events (AE) were reported.